Objective: Curability of malignant trophoblastic tumours. Design: Retrospective analysis. Setting: Trophoblastic Disease Centre (TDC-CZ) in the Czech Republic. Methods: Clinical and pathological analysis of 367 malignant trophoblastic tumours (MTT) from the point of histologic typing, risk degrees (RD) according to classification of FIGO, WHO, NIH and TDC-CZ and the evaluation of curability. Results: 1st RD and 2nd RD according to TDC-CZ classification include 85.1% MTT and its curabi- lity comprises 100%. At 3rd RD cure rate drops to 64.3% and at 4th RD to 55.6%. According to FIGO classification 1st RD comprises 48%, 2nd RD 17% and their cure rate is also 100%. The 3rd/a RD includes 20% and curability is 100%, 3rd/bc RD includes 10% with cure rata of 67% and 4th RD/abc comprises 5% with 50% curability. According to WHO 1 of RD (< 5 score) includes 81,2% and cure rate 99,2%. 2nd RD (= 5-7 score) has 9.1% and 92.9% cure rate. 3rd RD (8-12 score) comprises 4.5% and 57.1% cure rate and 4th RD (> 12 score) includes 5.2% with 50% cure rate. According to NIH 1st RD (=A) comprises 64.9% with 100% curability and 2nd RD (=B1) includes 20.1% with 100% curability. 3rd and 4th RD according to NIH B2 comprise 14.9% and have 60.9% curability. Curability depends on histologic type of MTT. In differentiated forms curability comprises 96.7% and in undifferentiated forms summarized 76.9%, fluctuating according to subtypes from 60% to 88.9%. Conclusion: Comparing the cure rate according to classification FIGO, WHO, NIH and TDC-CZ in 367 MTT treated in the TDC-CZ in the Czech Republic during the years 1955 - 2000 it becomes clear that relevant prognostic-risk classification must factually specify: 1. Staging with specific location of metastasis, 2. Independent risk factors verified by multifactorial analysis 3. Histolo- gic type with expression of differentiated and undifferentiated components of MTT.

        Key words: malignant trofoblastic tumours, typing, prognostic classifications, curability